GTGe Tan

Ge Tan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ge Tan has a total of 64 co-authors. Here are the top co-authors by number of shared publications:

  • Dongli Yuan

    Department of Intelligent Medical Systems, Chongqing Medical University, Chongqing, People’s Republic of China

    6 shared publications
  • Qin Li

    Department of Neurology, Chongqing General Hospital, Chongqing, People’s Republic of China

    5 shared publications
  • Qinlin Liu

    Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

    4 shared publications
  • Yixin Zhang

    Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China

    4 shared publications
  • Xiran Yu

    3 shared publications
  • Chuan Hu

    Department of Neurology, People’s Hospital of Bishan District, Bishan, People’s Republic of China

    2 shared publications

Latest Publications

  • Open Access

    Edge-centric functional diversity alterations and associated transcriptomic profiles of pain and vertigo in the migraine spectrum

    by Shuo Zhu, Liang Dong, Ruonan Zhang, Jingbo Zhang, Tong Zhu, Jing Min, Taocui Yan, Yuhang Yang, Yin Liu, Xumeng Zhu, et al.

    Background: The migraine spectrum exhibits substantial clinical heterogeneity, encompassing pain-dominant, vertigo-dominant, and pain-vertigo overlapping manifestations, as represented here by migraine without aura (MwoA), a clinically defined adult vertigo-dominant recurrent vestibular phenotype (hereafter, BPV group), and vestibular migraine (VM), respectively. However, the shared and symptom-preferential functional network alterations and their underlying molecular characteristics across these clinical phenotypes remain poorly understood, hindering individualized precision interventions. Methods: Resting-state fMRI data were acquired from 106 patients within the migraine spectrum (16 BPV, 61 MwoA, and 29 VM) and 39 healthy controls (HC). An edge-centric connectome framework was applied to identify overlapping network communities, and regional functional diversity was quantified using normalized entropy. Gene expression profiles and neurotransmitter receptor/transporter maps were integrated to identify molecular patterns spatially associated with aberrant functional diversity. Results: All patient groups showed significant functional diversity alterations in the ventral attention network and left precuneus that correlated with symptom severity. MwoA and VM exhibited divergent functional diversity in sensorimotor regions but shared associations with serotonergic maps; BPV and VM shared cerebellar increases associated with gamma-aminobutyric acid type A receptor distribution. VM further exhibited reduced functional diversity in the thalamus and insula, with molecular associations involving genetic homeostasis and glial cell processes. Conclusions: Across the migraine spectrum, these distinct clinical phenotypes share network abnormalities related to higher-order attentional regulation, while the pain-containing and vertigo-containing phenotypes exhibit preferential alterations involving pain processing and vestibular regulation, respectively, with the pain-vertigo overlapping phenotype further showing additional abnormalities involving multimodal sensory integration and molecular homeostatic processes. This study delineates shared and symptom-preferential neural signatures across pain-dominant, vertigo-dominant, and pain–vertigo overlapping clinical phenotypes, providing new insights for individualized clinical assessment and precision interventions.

  • Open Access

    Evaluating the efficacy of rimegepant as a preventive treatment for chronic and episodic migraine: a three-month longitudinal retrospective cohort study

    by Hamza Khan, Muhammad Saqib Khan, Sheraz Khan, Fang Liu, Quan Feng, Irfan Ahmad, Ge Tan

    Background: Rimegepant, an oral calcitonin gene-related peptide receptor antagonist approved for both acute and preventive migraine treatment, demonstrates efficacy in clinical trials, but real-world evidence remains limited. This study examined the association between rimegepant use and changes in migraine frequency and patient-reported outcomes in a real-world clinical setting. Methods: This retrospective cohort study conducted at The first affiliated hospital of Chongqing Medical University, analyzed medical records of 40 adults (aged 18–65 years) with chronic ( n = 21) or episodic migraine ( n = 19) who received rimegepant 75 mg every other day for 3 months. Primary outcomes were changes in monthly headache days (MHD) and monthly migraine days (MMD) from baseline. Secondary outcomes included: Headache Impact Test-6 (HIT-6), Migraine Disability Assessment (MIDAS), and Migraine-Specific Quality of Life Questionnaire (MSQ). Results: Forty participants (mean age 41.12 ± 10.86 years; 80% women) were included, comprising 21 with chronic migraine and 19 with episodic migraine. All five outcome measures improved significantly from baseline to Month 3 (all P = 0.001). Monthly migraine days decreased from 17.27 ± 8.52 to 2.90 ± 2.91, and monthly headache days from 19.10 ± 7.46 to 5.60 ± 3.81. HIT-6 and MIDAS scores declined markedly (62.27 to 45.47 and 50.99 to 12.44, respectively), while MSQ scores improved from 59.94 to 86.53. Both chronic and episodic migraine subgroups showed significant improvements across all outcomes, with the greatest reductions in headache frequency occurring between baseline and Month 1. By Month 3, outcome values were comparable between subgroups despite substantial baseline differences. Conclusions: In this retrospective cohort of patients with prior inadequate response to preventive therapy, Every-other-day rimegepant was associated with meaningful reductions in migraine frequency and headache-related disability over 3 months in both chronic and episodic migraine patients. These preliminary findings are encouraging but require confirmation in prospective controlled studies.

  • Open Access

    Effectiveness and Safety of Noninvasive Neuromodulation for Migraine Prevention: A Network Meta‐Analysis

    by Quan Feng, Fang Liu, Na Li, Xiran Yu, Lu Ning, Yichen Li, Ge Tan

    Background: Migraine, a common chronic neurovascular disorder, has a global incidence rate of approximately 14%. Limited evidence exists for clinical decision‐making related to migraine preventive treatment via noninvasive neuromodulation. To bridge this gap, we conducted a network meta‐analysis (NMA) aimed at comparing and ranking the efficacy and safety of diverse noninvasive neuromodulation treatments in preventing migraine. Methods: We systematically searched for randomized controlled trials (RCTs) in four databases and included the final articles through strict screening. Subsequently, we carried out data extraction and quality assessment. Then, an NMA (PROSPERO ID CRD42024617371) based on the frequentist model was performed. Finally, we drew conclusions based on the surface under the cumulative ranking curve (SUCRA) and the league table. Results: Twenty four RCTs involving 2347 patients were included. Although no modality significantly reduced monthly migraine days versus placebo ( p > 0.05), percutaneous mastoid electrical stimulation (PMES) emerged as the most effective and safest intervention (SUCRA: 78.8%) compared with placebo in achieving a 50% responder rate (OR = 16.58, 95% CI: 5.17, 53.17) and reducing monthly acute antimigraine medication use (MD = −0.90, 95% CI: −1.28, −0.52). Noninvasive vagus nerve stimulation (nVNS) exhibited the best safety profile (SUCRA: 72.2%) when high‐risk trials were excluded. Conclusion: Among the noninvasive neuromodulation interventions discussed, PMES appears to be a favorable choice for migraine prevention, pending verification through cross‐regional investigations. And nVNS shows the best safety profile when high‐risk trials were excluded.

  • Open Access

    Telemedicine efficacy and satisfaction of patients and headache specialists in migraine management

    by Qinlin Liu, Fang Liu, Xiran Yu, Jiali Zang, Ge Tan

    Background: Migraine follow-up is difficult for outpatients, especially after the COVID-19 pandemic, we tried to identify the most appropriate telemedicine methods for migraine in terms of efficacy, safety, patient compliance, and patient and physician satisfaction.Methods: Migraine patients were screened from the Headache Center of the First Affiliated Hospital of Chongqing Medical University from September 2019 to December 2021 and randomly classified into an outpatient group and four telemedicine groups: social software, telephone, E-mail, and short message. Headache specialists followed up with the patients 3 and 6 months after their visit and asked about their satisfaction with the follow-up in each instance, as were the headache specialists.Results: A total of 147 migraine patients were included, of whom 65 completed the follow-up. After 3 and 6 months of follow-up, the proportion of patients whose monthly headache frequency decreased by over 50% in the social-software, telephone, and E-mail groups was no different from that in the outpatient group. A similar result was obtained from evaluations with the Visual Analog Scale, the Headache Impact Test and the Migraine Disability Assessment compared with baseline in social software and telephone groups. The compliance in social-software group was not worse than that in the outpatient group. The proportion of patients in the E-mail group who completed the follow-up and the proportion of patients in the telephone group who consistently took preventive medication were significantly lower than those in the outpatient group. After 6 months, the majority of patients in the outpatient, social-software, and telephone groups and headache specialists in the outpatient, social-software groups were satisfied with the follow-up, while fewer patients in the E-mail group and fewer specialists in the telephone and E-mail group showed their satisfaction.Conclusion: Compared with outpatient visits, it is safe and effective to use social software and telephone to follow up on migraine patients, and E-mail and short-message follow-up have lower feasibility. Migraine patients prefer social-software and telephone follow-up, while specialists prefer social-software follow-up.


  • Open Access

    Therapy for Psychiatric Comorbidities in Patients with Episodic Cluster Headache: A Prospective Multicenter Study

    by Qinlin Liu, Yixin Zhang, Chuan Hu, Dongli Yuan, Kuiyun Wang, Wen Fan, Feibao Pan, Qin Li, Yunfeng Wang, Ge Tan

    Purpose: To explore changes of depression, anxiety and sleep disturbance in patients with episodic cluster headache inside and outside the attack period and assess the therapy to improve the treatment. Patients and Methods: We prospectively recruited 396 patients from 11 specialized headache outpatients and analyzed their headache characteristics, Hospital Anxiety Depression Scale scores, Pittsburgh sleep quality index scores, and the usage of psychiatric medications during as well as 1 month after the attack period. Results: A total of 220 patients completed the follow-up, 52.73% of whom had anxiety, 47.27% had depression and 49.09% had sleep disturbance inside the attack period. At follow-up, the percentage of these patients significantly decreased to 16.36%, 21.82% and 14.55% in the remission period, respectively (p < 0.05). Antidepressants and mood stabilizers were prescribed to 58.18% of the patients. However, both of the changes of Hospital Anxiety Depression Scale scores after the end of the attack period for anxiety (3.52± 2.91 vs 3.32± 3.09, p =0.61) and depression (3.41± 3.33 vs 2.90± 3.58, P =0.28) were comparable in patients with and without taking these medications. Nocturnal onset of headache was positively correlated with Pittsburgh score (OR=8.71), anxiety (OR=2.33) and depression scores (OR=3.56) (p < 0.05). Conclusion: Depression, anxiety and sleep disturbance were significantly alleviated after the attack period. However, psychiatric medications showed limited effect on depression and anxiety. Additionally, the nocturnal attack may cause anxiety and depression in episodic cluster headache.


  • Open Access

    Headache attributed to transient ischaemic attack: a prospective retrospective baseline study

    by Ge Tan, Jiali Zang, Qing Liu, Qin Li, Qinlin Liu, Xiran Yu

    Background: It is difficult to discriminate between headache attributed to transient ischaemic attack from migraine with aura. We studied the characteristics of headache-attributed transient ischaemic attacks to provide clinical evidence for the treatment of headache attributed to transient ischaemic attack.Methods: We performed a prospective study with a retrospective baseline evaluation of all patients with headaches attributed to transient ischaemic attack (22) during a three-year period. The demography, vascular risk factors and clinical information were collected. The following typical symptoms were evaluated by an ABCD2 score of 4 or greater. The headache characteristics were collected within a 24-hour interval after the onset of transient ischaemic attack.Results: Headache that is attributed to transient ischaemic attack accounted for 8.2% (22/269) of the patients with transient ischaemic attack. Headache attributed to transient ischemic attack was more common in women (68.2%, 15/22) and in posterior circulation of transient ischemic attack (59.1%,13/22). These types of headaches were similar to tension-type headache and included a bilateral location (72.7%, 16/22), a dull quality (72.7%, 16/22), and a moderate intensity (54.5%, 12/22).Conclusions:Our study showed that headache attributed to transient ischaemic attack was similar to a tension-type headache and was more common in women and in patients with posterior circulation transient ischaemic attacks.

  • Open Access

    Advances in topiramate as prophylactic treatment for migraine

    by Chuan Hu, Yixin Zhang, Ge Tan

    It is well‐known that topiramate as a kind of antiepileptic drug has been proved effective for migraine prevention in North America and Europe. However, topiramate is still viewed as an off‐label medication for migraine treatment in China, partly because of the limited evidence in Chinese patients. We summarize the effects of topiramate on the frequency, severity, quality‐of‐life, and adverse event among migraine patients, including children and adolescent in this review, so as to provide reference for Chinese doctors.


  • Open Access

    Headache in the Emergency Department in Chongqing Province, China: A Multicentre Study

    by Qin Li, Tao Ye, Jingxi Ma, Dongli Yuan, Xuemei Peng, Min Cai, Zhengwei Xi, Yujiao Zhang, Qinlin Liu, Ge Tan

    Background: To investigate the present situation of emergency headache in many general hospitals in Chongqing Province, China.Methods: From January 1 to December 31, 2017, we studied patients who complained of headaches as the main symptom in the emergency department of 17 general hospitals in Chongqing Province. Each patient with a headache was interviewed and the medical history was collected by administering a questionnaire. The diagnosis of headache is based on the third edition of the International Classification of Headache Disorders (ICHD-3 beta). Results: In 2017, 16434 patients complained of headache in 17 general hospitals in Chongqing, accounting for 2.3% of all emergency patients. Eight thousand one male patients (48.7%) and 8433 female patients (51.3%) experienced a headache. The average age was (41.8 ± 13.2) years, and the course of disease was 3 hours to 15.2 years. Regarding the initial diagnosis, 7299 patients (44.4%) were diagnosed secondary headache, 5076 (30.9%) were diagnosed with primary headache and 4059 (24.865%) could not be diagnosed. The hospitalization rates for these patients were 60.3%, 12.2%, and 41.5%, respectively. Migraine is still the most common type of primary headache. Conclusions: This study shows that the misdiagnosis rate and missed diagnosis rate of patients with an emergency headache are high, and the emergency department still performs overtesting and hospitalizations.

  • Open Access

    Headache in the emergency department in Chongqing Province, China: A multicentre study

    by Qin Li, Tao Ye, Jingxi Ma, Dongli Yuan, Xuemei Peng, Min Cai, Zhengwei Xi, Yujiao Zhang, Qinlin Liu, Ge Tan

    Background: To investigate the present situation of emergency headache in many general hospitals in Chongqing Province, China.Methods: From January 1 to December 31, 2017, we studied patients who complained of headaches as the main symptom in the emergency department of 17 general hospitals in Chongqing Province. Each patient with a headache was interviewed and the medical history was collected by administering a questionnaire. The diagnosis of headache is based on the third edition of the International Classification of Headache Disorders (ICHD-3 beta). Results: In 2017, 16434 patients complained of headache in 17 general hospitals in Chongqing, accounting for 2.3% of all emergency patients. Eight thousand one male patients (48.7%) and 8433 female patients (51.3%) experienced a headache. The average age was (41.8 ± 13.2) years, and the course of disease was 3 hours to 15.2 years. Regarding the initial diagnosis, 7299 patients (44.4%) were diagnosed secondary headache, 5076 (30.9%) were diagnosed with primary headache and 4059 (24.865%) could not be diagnosed. The hospitalization rates for these patients were 60.3%, 12.2%, and 41.5%, respectively. Migraine is still the most common type of primary headache. Conclusions: This study shows that the misdiagnosis rate and missed diagnosis rate of patients with an emergency headache are high, and the emergency department still performs overtesting and hospitalizations.